Synairgen PLC will present findings next month that show that its SNG001 drug reduced the relative risk of recognised symptoms of long Covid compared to placebo.
The findings are based on analysis of data from 60- and 90-day follow-up visits to patients hospitalised with Covid-19, some of which were treated with SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta.
Analysis showed that when compared to placebo, SNG001 reduced the relative risk of recognised symptoms of long Covid at day 60 and/or day 90.
For fatigue and or malaise the relative risk reduction was 35.4%, for shortness of breath it was 28.3% and for loss of smell and/or taste it was 61.4%.
Professor Chris Brightling, NIHR senior investigator at the Department of Respiratory Sciences at the University of Leicester, said: "This promising long Covid data is very welcome in an area of enormous clinical need. While it merits further investigation, it is exciting to see that SNG001 may have a positive effect in reducing some of the most recognised and problematic symptoms associated with long Covid which afflicts millions of people and for which there are no current treatments."
Synairgen chief executive Richard Marsden said the data “adds to our rationale of supporting further development and investigation of SNG001 as a broad-spectrum antiviral for severe respiratory infections."
The company said it will present findings from the analysis from ‘SPRINTER’ trial data at the IDWeek 2022 conference to be held 19-23 October in Washington, DC.
Read more on Proactive Investors UK